Blue Shield of California is set to offer Humira, one of the world’s top-selling drugs, for free. “We want to be able to present the price to our membership so that they can make the choice.” There’s also a profit motive: Blue Shield of California currently spends more than $100 million a year on Humira, Gibbs said, more than any …
By Patrick Wingrove Aug 26 - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead. Although 10 Humira biosimilars have launched in the U.S. since January 2023 from drugmakers including Amgen and Pfizer, AbbVie …
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth. Elahere brought in $105.2 million in revenue in …
Humira has enjoyed high-priced U.S. exclusivity for 20 years, making it the best-selling drug in history. How AbbVie maintains market share One of AbbVie’s strategies was to warn health plans that if they recommended biosimilars over Humira they would lose rebates on purchases of Skyrizi and Rinvoq, two drugs with no generic imitators that are each listed at about $120,000 …
Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. Instead, it depends on their prescription drug coverage, which might still bring large bills until a plan’s deductible is met. PBMs negotiate confidential deals with drugmakers that can influence whether a biosimilar …
